According to the COSMIC database, PRPRN2 and SORCS2 point mutations were detected in ∼18% and ∼13% of breast cancer samples, and ∼26% and ∼16% of prostate cancer samples, respectively (92). Here, SORCS2 is linked to prostate cancer.